Avanos: Vanguard reports 0 shares beneficially owned
Avanos Medical Inc — The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting that, after an internal realignment, it holds 0 shares of Avanos common stock, equal to 0% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avanos Medical Inc — The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting that, after an internal realignment, it holds 0 shares of Avanos common stock, equal to 0% of the class. The amendment explains certain Vanguard subsidiaries now report beneficial ownership separately following an internal realignment on January 12, 2026.
Insights
Vanguard disaggregated holdings and now reports no beneficial ownership in Avanos.
The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report beneficial ownership separately and The Vanguard Group no longer claims beneficial ownership over those subsidiaries' holdings. The Schedule 13G/A amendment reports 0 shares and 0% ownership.
Cash‑flow treatment and any holdings now reported by separate subsidiaries are not included here; subsequent filings by those subsidiaries may disclose holdings if applicable.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the Schedule 13G/A amendment say about Avanos (AVNS)?
Who signed the Schedule 13G/A amendment for Vanguard?
AI-generated analysis. How Rhea-AI works. Not financial advice.